Literature DB >> 23489365

FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma.

Paul M Putora1, Martin Früh, Joachim Müller.   

Abstract

Previous reports suggest a correlation between positron emission tomography with fluorodeoxyglucose maximum standardized uptake value (SUVmax) and epidermal growth factor receptor (EGFR) mutation status in lung cancer. We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild-type EGFR adenocarcinomas. The mean SUV value was 10.7 for EGFR-mutated adenocarcinomas and 9.9 for wild-type tumours. There was no correlation between SUV values and EGFR mutation status. Omitting EGFR testing in lung cancers with low SUVmax is not appropriate.
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23489365     DOI： 10.1111/resp.12083

Source DB:  PubMed          Journal:  Respirology        ISSN： 1323-7799            Impact factor:   6.424


  12 in total

1.  Autoclustering of Non-small Cell Lung Carcinoma Subtypes on (18)F-FDG PET Using Texture Analysis: A Preliminary Result.

Authors:  Seunggyun Ha; Hongyoon Choi; Gi Jeong Cheon; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-06-11

2.  PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?

Authors:  Victor H Gerbaudo; Chun K Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-10-11

3.  Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma.

Authors:  Il Ki Hong; Jeong Mi Lee; In Kyoung Hwang; Seung Sook Paik; Chanwoo Kim; Seung Hyeun Lee
Journal:  Cancer Manag Res       Date:  2020-07-28       Impact factor: 3.989

4.  FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Authors:  Hyun Woo Chung; Kye Young Lee; Hee Joung Kim; Wan Seop Kim; Young So
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-06       Impact factor: 4.553

Review 5.  Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  Chi Chiu Leung; José M Porcel; Kazuhisa Takahashi; Marcos I Restrepo; Pyng Lee; Claire Wainwright
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

6.  The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.

Authors:  Ao Liu; Anqin Han; Hui Zhu; Li Ma; Yong Huang; Minghuan Li; Feng Jin; Qiuan Yang; Jinming Yu
Journal:  Oncotarget       Date:  2017-05-16

Review 7.  Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

Authors:  Robin W Jansen; Paul van Amstel; Roland M Martens; Irsan E Kooi; Pieter Wesseling; Adrianus J de Langen; Catharina W Menke-Van der Houven van Oordt; Bernard H E Jansen; Annette C Moll; Josephine C Dorsman; Jonas A Castelijns; Pim de Graaf; Marcus C de Jong
Journal:  Oncotarget       Date:  2018-04-13

8.  Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma.

Authors:  Wonseok Whi; Seunggyun Ha; Sungwoo Bae; Hongyoon Choi; Jin Chul Paeng; Gi Jeong Cheon; Keon Wook Kang; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-06-14

9.  Alternative and New Radiopharmaceutical Agents for Lung Cancer.

Authors:  Silvi Telo; Letizia Calderoni; Sara Vichi; Federico Zagni; Paolo Castellucci; Stefano Fanti
Journal:  Curr Radiopharm       Date:  2020

10.  Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.

Authors:  Arthur Cho; Jin Hur; Yong Wha Moon; Sae Rom Hong; Young Joo Suh; Yun Jung Kim; Dong Jin Im; Yoo Jin Hong; Hye-Jeong Lee; Young Jin Kim; Hyo Sup Shim; Jae Seok Lee; Joo-Hang Kim; Byoung Wook Choi
Journal:  BMC Cancer       Date:  2016-03-16       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.